NCT07388771 Prediction of Outcome to Neoadjuvant Therapy in Non-small Cell Lung Cancer（NSCLC）
| NCT ID | NCT07388771 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Qian Chu |
| Condition | NSCLC |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2025-12-01 |
| Primary Completion | 2026-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2025-12-01 with a primary completion date of 2026-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This observational study aims to construct and validate the performance of a multimodal predictive model in forecasting the outcomes of neoadjuvant therapy in patients with NSCLC. The core research question is: Can a multi-model approach predict outcomes of neoadjuvant therapy for non-small cell lung cancer and provide clinical recommendations?
Eligibility Criteria
Inclusion Criteria: 1. pathologically diagnosed non-small cell lung cancer 2. The treatment plan is：receiving neoadjuvant chemo-immunotherapy during the study period, followed by surgical resection Exclusion Criteria: 1. recurrent or metastatic lung cancer; 2. patients with other primary tumors
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07388771 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying NSCLC. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07388771 currently recruiting?
Yes, NCT07388771 is actively recruiting participants. Contact the research team at huminghao2010@126.com for enrollment information.
Where is the NCT07388771 trial being conducted?
This trial is being conducted at Wuhan, China, Hangzhou, China.
Who is sponsoring the NCT07388771 clinical trial?
NCT07388771 is sponsored by Qian Chu. The trial plans to enroll 500 participants.